The global life sciences and healthcare sectors are undergoing a massive technological evolution, spurred by automation, artificial intelligence (AI), and next-generation therapeutic modalities. In a significant move impacting the transatlantic biotechnology landscape, newly formed private equity advisory firm Prime Radiant Partners (“Prime Radiant”) has announced a $50 million growth equity investment in Cellares.
The investment was executed via the Prime Radiant Fund SLP SICAV-RAIF, a Luxembourg-based alternative investment fund advised by the firm. This transaction marks the firm’s inaugural investment since its official launch in 2025.
This $50 million commitment forms a vital part of Cellares’ larger $327 million Series D funding round. The capital injection will directly support Cellares' mission to alleviate manufacturing bottlenecks in the cell and gene therapy (CGT) sectors, accelerate patient access to life-saving living drugs, and expand its global footprint of automated, scalable manufacturing facilities across North America, Europe, and Asia.
The Transatlantic Private Equity Play: Driving Healthcare Innovation
Headquartered across key international financial and biotech hubs with offices in New York, Milan, and Munich, Prime Radiant focuses specifically on middle-market private equity opportunities. The firm targets high-growth, innovation-driven companies delivering critical outsourced services, drug production technologies, and healthcare software solutions across North America and Europe.
Founded by veteran industry executives Giovanni Fazio, Walid Gardezi, and Peter Soelkner, the Prime Radiant leadership team brings more than 70 years of collective operational and investment experience across private equity, life sciences, and pharmaceutical services. By deploying its first major allocation into Cellares, the firm signals its deep conviction in automated, Industry 4.0 infrastructure as the future of the global bioeconomy.
Dissecting Cellares’ IDMO Model: Overcoming the CDMO Bottleneck
Traditional cell therapy manufacturing relies heavily on conventional Contract Development and Manufacturing Organizations (CDMOs). These legacy frameworks suffer from high labor requirements, large cleanroom footprints, high production costs, and an elevated risk of human error or process failure.
Cellares directly disrupts this outdated system by establishing itself as the world’s first Integrated Development and Manufacturing Organization (IDMO).
Core Advantages of the Cellares IDMO Architecture:
Massive Throughput Scaling: The proprietary platform allows biopharmaceutical clients to produce up to 10 times more cell therapy batches than conventional CDMOs within an equivalent physical facility footprint and headcount.
Substantial Cost Reduction: By replacing manual interventions with end-to-end hardware and software integration, Cellares delivers significantly lower per-patient manufacturing costs.
Minimized Process Failure Rates: Closed, automated systems systematically remove manual touchpoints, driving down contamination risks and ensuring high reproducibility.
Dual-Platform Synchronization: The ecosystem relies on the Cell Shuttle® for end-to-end automated physical manufacturing alongside Cell Q™ for automated, real-time, in-process quality control and release testing.
Regulatory Validation and Global Operational Footprint
Cellares has transitioned from an advanced development-stage technology provider into a fully validated, clinically operational manufacturing powerhouse. The platform has achieved critical milestones that confirm its readiness for global commercialization across multiple therapeutic indications, including oncology and autoimmune diseases.
Key Milestones and Expansion Indicators:
FDA Designation: The Cell Shuttle is the first cell therapy manufacturing platform to receive the U.S. Food and Drug Administration's (FDA) Advanced Manufacturing Technology (AMT) designation, registering a 100% automation success rate across more than a dozen distinct processes.
Clinical Trial Validation: The platform successfully achieved an Investigational New Drug (IND) Amendment, enabling active clinical manufacturing on the Cell Shuttle and leading to the successful dosing of the first patients in an active partner clinical trial.
Strategic Manufacturing Footprint: Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. To build a resilient global supply chain, additional commercial-scale smart facilities are currently under construction in Europe and Japan.
A High-Caliber Global Investor Coalition
By anchoring its inaugural deal within Cellares’ Series D round, Prime Radiant joins a sophisticated group of global institutional life sciences and growth technology investors. This collaborative capitalization highlights the market's collective demand for standardized, automated biotechnology infrastructure.
Prominent Series D Co-Investors Include:
Institutional Asset Managers: Funds managed by BlackRock, T. Rowe Price Investment Management, Inc., and Baillie Gifford.
Venture Capital & Growth Specialists: Eclipse, DFJ Growth, and ARK Invest.
Sovereign Wealth & Strategic Corporate Venture Arms: EDBI (Singapore), Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures, and Willett Advisors.
Executive Perspectives: Scaling Sustainable Bio-Infrastructure
The transaction brings together deep operational expertise and specialized sector capital to fundamentally reshape how advanced biologics move from the laboratory environment directly to the patient’s bedside.
Walid Gardezi, Co-Founder and Partner at Prime Radiant, noted:
"The global healthcare market is undergoing a significant period of transformation driven by the launches of next-generation therapies and adoption of advanced technologies to improve patient care, while facing crosscurrents from increased regulatory complexity and aging populations across the world. Cellares represents our strategy at work as we seek to partner with exceptional management teams and companies to accelerate growth and drive innovation to improve human health."
Fabian Gerlinghaus, Co-Founder and CEO of Cellares, highlighted the value of operationally grounded capital:
"Prime Radiant's founders built their careers inside drug production and outsourced pharma services, so they understand the economics of the model Cellares is reshaping from firsthand experience. When investors with that background make you their first investment, it reflects real conviction in Cellares’ IDMO model which integrates world-class tools and integrated automation to offer global biopharmaceutical manufacturing services. As we expand our network of IDMO Smart Factories into the United States, Europe, and Japan, their operational expertise will be invaluable."
Peter Soelkner, Co-Founder and Partner at Prime Radiant, added:
"Cellares is a company with world-class technology and a unique value proposition, which has the potential to fundamentally change market dynamics and how cell therapies reach patients at scale globally. We look forward to supporting Fabian and his team alongside a distinguished group of co-investors as they continue to scale and expand their footprint globally."
Giovanni Fazio, Co-Founder and Partner at Prime Radiant, stated:
"Our inaugural investment reflects both the strength of the Cellares platform and our conviction in the future of cell and gene therapy manufacturing. It is the first chapter in advising what we believe will be a distinctive portfolio of companies driving the next phase of healthcare and life sciences innovation, and we are just getting started."
Through this transatlantic growth capital injection, Prime Radiant positions its advised fund at the absolute forefront of the automated bioeconomy, addressing the primary capacity and economic constraints currently limiting the scalability of 21st-century medicine.
